

Contents

Abbreviations	8
General abbreviations	8
Human genes and proteins	9
Summary	10
1 Introduction.....	11
1.1 Genodermatoses	11
1.2 Epidermodysplasia verruciformis	13
1.2.1 Clinical picture of EV	13
1.2.2 Human papilloma viruses	13
1.2.3 Role of human papilloma viruses in EV	15
1.2.4 Human genetics of EV	18
1.2.5 Atypical EV	21
1.3 Ichthyosis with confetti	22
1.4 Aim of the study	24
2 Materials and methods.....	25
2.1 Investigations of patient samples	25
2.1.1 EV patients	25
2.1.2 Isolation of nucleic acids from human samples	27
2.1.3 Sequencing of <i>TRADD</i> and <i>CIB1</i>	27
2.1.4 Exon-specific expression of <i>TMC6</i> and <i>TMC8</i> transcripts	28
2.1.5 Sequencing of <i>TMC8</i> cDNA	28
2.1.6 <i>CIB1</i> expression in EV patients	28
2.1.7 Validation of antibodies for IF	28
2.2 General cell culture work	30
2.2.1 Cell lines and cell culturing	30
2.2.2 Validation of keratinocyte line NKc21	30
2.2.3 Transfection of NKc21 cells	31
2.3 Design and cloning of CRISPR/Cas9 and TALEN plasmids	32
2.3.1 Production of chemocompetent <i>E. coli</i> and transformation	32
2.3.2 Cloning of TALEN plasmids	32
2.3.3 Cloning of CRISPR/Cas9 plasmids	33
2.4 EV model cell line	34
2.4.1 Strategies for generation of EV model cell lines	34
2.4.2 Evaluation of genome editing efficiency	34
2.4.3 FACS / single cell sorting	36
2.4.4 Expansion and screening of clones by direct PCR	36
2.4.5 Evaluation of clones by PCR and sequencing	36

2.4.6	Verification of <i>CIB1</i> knockout by RT-PCR	37
2.4.7	Control clones	37
2.4.8	Verification of <i>CIB1</i> knockout by Western blot	37
2.4.9	SNP array of clones	37
2.4.10	Proliferation assay	38
2.4.11	RNA-Seq	38
2.4.12	Validation of RNA-Seq results by qRT-PCR	38
2.4.13	Gene expression in samples of EV patients	39
2.5	IWC model cell line	40
2.5.1	Strategy	40
2.5.2	Evaluation of efficiency	40
2.5.3	Generation of clones	40
2.5.4	Proliferation assays	41
2.5.5	Differentiation of keratinocytes	41
2.5.6	Sequencing of cDNA	41
2.5.7	RNA-Seq	41
2.5.8	Immunofluorescence of differentiated cells	42
2.5.9	Production of epidermal models	42
2.5.10	Immunofluorescence of epidermal models	43
3	Results	44
3.1	Investigations of patient samples	44
3.1.1	Sanger sequencing of <i>TRADD</i> and <i>CIB1</i>	44
3.1.2	Effects of <i>TMC8</i> splice site mutation	46
3.1.3	Expression of <i>CIB1</i> in EV patients	48
3.1.4	Validation of antibodies for IF	49
3.2	Validation of keratinocyte line NKc21	53
3.3	EV cell line model	54
3.3.1	Evaluation of genome editing efficiency	54
3.3.2	Expansion and screening of clones	54
3.3.3	Control clones	56
3.3.4	Validation of knockout clones	57
3.3.5	SNP array	59
3.3.6	Genotype of <i>CIB1</i> knockout clones	62
3.3.7	Proliferation assays	64
3.3.8	RNA-Seq	65
3.3.9	Validation of RNA-Seq results by qRT-PCR	71
3.3.10	Verification of model cell line gene expression in EV patients	72
3.4	IWC cell line model	73
3.4.1	Evaluation of genome editing efficiency	73
3.4.2	Characterization of cell lines	73

3.4.3	Proliferation assay	75
3.4.4	Keratinocyte differentiation	76
3.4.5	Analysis of differentiation by RNA-Seq	77
3.4.6	Subcellular localization of keratins in epidermal models	80
4	Discussion	83
4.1	Genetic and functional investigations on EV patients	83
4.1.1	A novel genetic etiology for EV	83
4.1.2	Effect of <i>TMC8</i> splice site mutation	84
4.1.3	Validation of antibodies for IF	85
4.2	Generation of cell line models	87
4.2.1	Validation of keratinocyte line NKc21	87
4.2.2	Generation of EV cell line model	87
4.2.3	Generation of IWC cell line model	89
4.3	Functional studies using the developed cell line models	90
4.3.1	Changes in gene expression caused by <i>CIB1</i> deficiency and <i>CIB1</i> function	90
4.3.2	Subcellular localization of keratins in IWC	94
5	Conclusions and outlook	97
6	Appendix	99
6.1	Supplementary materials and methods	99
6.1.1	Standard PCR protocol	99
6.1.2	Standard protocol for agarose gel electrophoresis and Sanger sequencing	99
6.1.3	Standard qRT-PCR protocol	102
6.1.4	Primer sequences	103
6.1.5	TALEN and CRISPR plasmids	105
6.1.6	Antibodies	107
6.1.7	Suppliers of reagents, kits, instruments, and software	108
6.2	Supplementary results	111
7	References	125
8	Acknowledgements	138
9	Curriculum vitae	140